How has been the historical performance of the Titan Biotech?

Answer:The historical performance of Titan Biotech shows a fluctuating trend in key financial metrics over the years. Breakdown: Titan Biotech's net sales have seen a gradual increase from Rs 64.91 crore in March 2019 to Rs 164.07 crore in March 2024, although it dipped to Rs 156.45 crore in March 2025. The total operating income followed a similar trend, peaking at Rs 164.07 crore in March 2024 before declining. The company's total expenditure, excluding depreciation, has risen from Rs 56.05 crore in March 2019 to Rs 131.02 crore in March 2025, indicating increased operational costs. Operating profit (PBDIT) has fluctuated, reaching a high of Rs 46.92 crore in March 2021 but dropping to Rs 29.34 crore in March 2025. Profit before tax also peaked at Rs 42.71 crore in March 2021, declining to Rs 24.37 crore in March 2025. The profit after tax followed a similar pattern, with a high of Rs 31.71 crore in March 2021 and a decrease to Rs 18.27 crore in March 2025. The consolidated net profit has also decreased from Rs 30.34 crore in March 2021 to Rs 21.53 crore in March 2025. On the balance sheet, total assets increased from Rs 64.73 crore in March 2019 to Rs 156.58 crore in March 2024, while total liabilities rose from Rs 64.73 crore to Rs 156.58 crore in the same period. Cash flow from operating activities remained stable around Rs 21 crore in the last two years, but the net cash outflow was noted in March 2024 at Rs 2 crore. Overall, Titan Biotech has shown growth in sales and assets but has faced challenges in maintaining profitability in recent years.